中药肺积方治疗晚期非小细胞肺癌104例临床研究

目的：研究中药肺积方治疗晚期非小细胞肺癌患者的临床疗效和作用机理。方法：患者104例随机分为三组：中药组予中药肺积方治疗；西药组常规化学治疗；中西组肺积方与化疗结合治疗。结果：近期疗效：KPS评分三组治疗后均高于治疗前，提高幅度中药组优于中西组，中西组又优于西药组（P<0.01）。远期疗效：三组患者平均生存时间、中位生存期、0.5年生存率、1年生存率均显示中西组高于中药组和西药组（P<0.05），中药组和西药组生存期相当（P>0.05）。TNF-α三组治疗后均低于治疗前，下降幅度中药组优于中西组，中西组又优于西药组（P<0.05）。结论：中药肺积方对晚期NSCLC具有一定的客观疗效，主要表现为稳定病灶、提高生活质量、延长生存期。

Clinical research on treating 104 cases of advanced NSCLC with the Feiji recipe

Objective： To observe the effect of Feiji recipe in the treatment of advanced NSCLC. Methods： 104 advanced NSCLC patients were randomly divided into three groups： TCM group （27 cases）, modem medicine（MM） group （37 cases）, combined TCM with MM group （40 cases）. Results： Short-term effect： The KPS scores after treatment in all three groups were higher than the pre-treatment. The rise in TCM group was superior to combined TCM with MM group, combined TCM with MM group was superior to WM group （P〈0.01）. Long-term effect： The average survival time, median survival time, half year survival rate, lyear survival rate, and survival curves had shown that combined TCM with MM group was higher than that of TCM and MM group （P〈0.05）. TNF-α in three groups after treatment were lower than in the pre-treatment. The decrease in TCM group was superior to combined TCM with MM group, then combined TCM with MM group was superior to MM group （P〈0.05）. Conclusion： The Feiji recipe has certain objective efficacy on treating advancedNSCLC, mainly shows in stabilizing lesions, improving the QOL and prolonging survival.